These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26587996)

  • 1. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Abreu D; Ferreira JJ
    Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safinamide: first global approval.
    Deeks ED
    Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safinamide in the treatment of Parkinson's disease.
    Schapira AH
    Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
    Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R;
    Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safinamide: A Review in Parkinson's Disease.
    Blair HA; Dhillon S
    CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safinamide for symptoms of Parkinson's disease.
    Müller T
    Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safinamide (Newron Pharmaceuticals).
    Chazot PL
    Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safinamide: a new hope for Parkinson's disease?
    Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
    Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
    Müller T
    Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
    Stocchi F; Torti M
    Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safinamide for the treatment of Parkinson's disease.
    Dézsi L; Vécsei L
    Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
    Drugs R D; 2004; 5(6):355-8. PubMed ID: 15563241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
    Müller T; Foley P
    Clin Pharmacokinet; 2017 Mar; 56(3):251-261. PubMed ID: 27665574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
    Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
    Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
    Stocchi F; Borgohain R; Onofrj M; Schapira AH; Bhatt M; Lucini V; Giuliani R; Anand R;
    Mov Disord; 2012 Jan; 27(1):106-12. PubMed ID: 21913224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.